- In an article recently published online in Nature Medicine, researchers from MSKCC and Weill Cornell Medical have described a new mechanism to control the metastasis of cancer that could potentially be used as a novel diagnostic tool and treatment option.
- A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at MSKCC, reveals new information about the origin of tumors.
Author Archives: Mark
MSKCC in the News: May 22 – June 6
- MSKCC’s James Allison is quoted in a Bloomberg News article about findings that show therapies like the Bristol drug, that prompt killer T-cells to eliminate invaders, may work against many tumors.
- In a New York Times article, Chaya S. Moskowitz, a biostatistician at MSKCC, indicates that the breast cancer risk for those treated with high radiation doses for Hodgkin’s lymphoma is similar to that for women with mutations in the BRCA1 gene.
- Dr. Clifford A. Hudis of MSKCC is quoted in a New York Times article about a study that shows a drug, known as T-DM1, that delivers a powerful poison to tumors without some of the side effects of traditional treatments can delay the worsening of breast cancer and also appears to substantially prolong lives.
MSKCC in the News: May 3 – May 21
- Mary S. McCabe of MSKCC is quoted in an ABC News article about the new challenges that cancer surivors face.
- Oncology & Biotech News interviews MSKCC’s Andrew D. Zelenetz, MD, PhD.
- Scientists at Cold Spring Harbor Laboratory and MSKCC have amassed strong experimental evidence implying that commonly occurring large chromosomal deletions that are seen in many cancer types contain areas harboring multiple functionally linked genes whose loss, they posit, confers a survival advantage on growing tumors.